Compare TSLX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | MESO |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2011 | 2005 |
| Metric | TSLX | MESO |
|---|---|---|
| Price | $18.47 | $17.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $21.61 | N/A |
| AVG Volume (30 Days) | ★ 433.8K | 179.9K |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $629.74 |
| Revenue Next Year | $1.20 | $30.65 |
| P/E Ratio | $121.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $13.05 |
| 52 Week High | $24.79 | $21.50 |
| Indicator | TSLX | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 53.65 |
| Support Level | $17.20 | $16.56 |
| Resistance Level | $18.65 | $17.33 |
| Average True Range (ATR) | 0.33 | 0.47 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 21.55 | 32.80 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.